如果每个人都使用更便宜的药物安维汀，而不是更昂贵的雷珠单抗，那么医疗保障每年就可以节省数亿美元。
Medicare could save hundreds of millions of dollars a year if everyone used the cheaper drug, Avastin, instead of the costlier one, Lucentis.
美国食品和药品管理局还没有批准阿瓦斯汀用于眼部治疗，使用它来代替雷珠单抗可能会产生额外的安全风险，尽管这一风险也许很轻微。
The Food and Drug Administration has not approved Avastin for use in the eye, and using it rather than the alternative, Lucentis, might carry an additional, although slight, safety risk.
建议这些年轻人每月接受注射帕利珠单抗。
It's recommended that these youngsters receive monthly injections of palivizumab.
结果显示4株单抗与土曲霉、黑曲霉均有交叉反应。
Results indicated that 4 monoclonal antibodies all have cross-reactions with Aspergillus terreus and Aspergillus niger.
贝伐单抗是静脉给予每两至三个星期。
Bevacizumab is given intravenously every two to three weeks.
没有那些蛋白的患者使用曲妥单抗无效。
贝伐单抗治疗法与低概率的严重不良反应有关。
Bevacizumab treatment was associated with a low rate of serious adverse events.
在76周是，56%的贝利单抗治疗组具有反应。
By week 76, 56% of those on belimumab were considered responders.
单抗功能的研究扩展了对DAF 功能活性特点的认识。
Observation of effects of McAbs extended our knowledge about DAF .
法国及美国应用西妥昔单抗治疗直肠结肠癌最多，而芬兰最低。
The use of cetuximab for colorectal cancer was highest in France and the United States and lowest in Finland.
两项对联合应用贝伐单抗和西妥昔单抗的随机试验结果还须等待。
The results of two randomized trials looking at the combination of bevacizumab and cetuximab are awaited.
欧洲药品局emea已经限制西妥昔单抗和帕尼单抗在这些患者使用。
EMEA, the European Medicines Agency, has already restricted use of cetuximab and panitumumab to such patients.
因此，让我们回到抗癌药物上来，例如，晚期乳腺癌的药物-贝伐株单抗。
So if we go back, for example, to the drug bevacizumab in connection with advanced breast cancer...
但这些称为EGFR抑制因子如西妥昔单抗的药物对结肠癌的治疗还不是很有效。
But these drugs called EGFR inhibitors, such as cetuximab, have not been very effective against colon cancer.
目的观察贝伐单抗与化疗药物联合用于晚期结直肠癌一线治疗的近期疗效和安全性。
OBJECTIVE To evaluate the efficacy and safety of bevacizumab when added to first-line irinotecan-based chemotherapy in patients with metastatic colorectal cancer.
更多的利妥昔单抗组的患者在第一次注射后发生不良反应，大多数都是1或2级的。
More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion.
另外，相对于安慰机组，利妥昔单抗组的糖化血红蛋白和胰岛素必须量都明显较低。
The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin.
免疫抑制剂治疗，如利妥昔单抗，硫唑嘌呤和环磷酰胺，明显减少抗体水平和复发率。
Treatment with immunosuppressants such as rituximab, azathioprine and cyclophosphamide resulted in a marked reduction in antibody levels and relapse rates.
贝伐单抗，也是没有用的情况下鳞状细胞癌，因为它会导致出血，从这种类型的肺癌。
Bevacizumab is also not used in cases of squamous cell cancer, because it leads to bleeding from this type of lung cancer.
结论：我们的研究显示单次剂量的西妥昔单抗可以明显影响肿瘤增殖和炎症基因的表达。
Conclusion Our study showed that a single dose of cetuximab has a significant impact on the expression of genes involved in tumor proliferation and inflammation.
已报道有关利妥昔单抗的毒性表皮坏死，但毒性表皮坏死和苯达莫司汀的关系尚不确定。
Toxic epidermal necrolysis has been reported for rituximab, but the relationship of toxic epidermal necrolysis to bendamustine has not been determined.
然而，却有相当比例的患者的治疗使用了替非罗班——具有阿昔单抗的部分药理学特性。
However, a large proportion of patients in the community are treated with eptifibatide, an agent that shares some but not all pharmacological properties with abciximab.
HER2的异质性会影响HER 2阳性转移性乳腺癌患者曲妥珠单抗的效果和生存期。
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer.
例如，美国应用贝伐单抗治疗直肠结肠癌以及埃罗替尼治疗肺癌是欧洲平均水平的10倍。
For example, the use of bevacizumab for colorectal cancer and erlotinib for lung cancer in the United States was 10 times higher than the European average.
该研究中，302名患者接受吉西他滨合用贝伐单抗，300名患者接受吉西他滨和安慰剂。
The study researchers assigned 302 patients to receive Avastin and Gemzar and assigned an additional 300 patients to receive Gemzar plus placebo.
由美国食品与药品管理局批准治疗转移克隆癌的贝伐单抗，是血管内皮生长因子的单克隆抗体。
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, is approved by the US Food and Drug Administration for metastatic colon cancer.
治疗前先行活组织检查和血浆样本的采集，西妥昔单抗应用之前，CRT之前，即手术的时机。
Biopsies and plasma samples were taken before treatment, after cetuximab but before CRT, and at the time of surgery.
将高致敏患者采用PRA单抗原磁珠检测的抗hla特异性抗体的荧光强度转换为MESF单位。
Fluorescence intensity values of anti-HLA specific antibodies determined by Flow PRA single antigen beads of highly sensitized patients were converted into MESF units.
蛋白组学和微数列用来检测西妥昔单抗的分子有效性并且明确生物标记物对疗效的预测方面的作用。
Proteomics and microarrays were used to monitor the molecular response to cetuximab and to identify profiles and biomarkers to predict treatment efficacy.
在2006年6月，数据监测和安全委员会发现加用贝伐单抗并不能使患者受益，于是停止了该研究。
The study was halted prematurely in June 2006 when the Data Monitoring and Safety Board determined that there did not appear to be any benefit to patients in continuing to take bevacizumab.
应用推荐